Clinical trial
CPG 7909 Injection in Melanoma
NCT00070642 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00070642 |
|---|---|
| Title | CPG 7909 Injection in Melanoma |
| Official title | ProMune™ (CPG 7909 Injection) With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Melanoma |
| Intervention type | Drug |
| Interventions | CPG 7909 Injection, dacarbazine, Chemotherapy |
| Enrollment | 184 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Oct 8, 2003 |
| Last update posted | Feb 10, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: